Katalog der Deutschen Nationalbibliothek

Expertensuche ?

Servicezeiten in Frankfurt am Main ab 1. Dezember 2025: Montag bis Freitag 9–18 Uhr und Samstag 10–16 Uhr
Service hours in Frankfurt am Main from 1 December 2025: Monday to Friday 9:00-18:00 and Saturday 10:00-16:00

Leichte Bedienung, intuitive Suche: Die Betaversion unseres neuen Katalogs ist online! → Zur Betaversion des neuen DNB-Katalogs

24. Dezember 2025 bis 1. Januar 2026: Die Deutsche Nationalbibliothek bleibt an beiden Standorten geschlossen. Bestellte Medien werden am 2. Januar 2026 bereitgestellt. // 24 December 2025 to 1 January 2026: The German National Library will be closed at both locations. Ordered media will be made available on 2 January 2026.

Ergebnis der Suche nach: "Originator"
im Bestand: Gesamter Bestand

91 - 100 von 138

	91	Correction to: Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018 Enthalten in Advances in therapy Bd. 39, 30.8.2022, Nr. 11, date:11.2022: 5300
	92	Correction to: The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review Enthalten in Advances in therapy Bd. 38, 19.7.2021, Nr. 8, date:8.2021: 4602
	93	Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis Enthalten in Advances in therapy Bd. 36, 30.5.2019, Nr. 8, date:8.2019: 2086-2095
	94	Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis Enthalten in BioDrugs Bd. 35, 11.5.2021, Nr. 4, date:7.2021: 469-471
	95	Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018 Enthalten in Advances in therapy Bd. 39, 23.6.2022, Nr. 8, date:8.2022: 3711-3734
	96	Discrepancies Between the Labels of Originator and Generic Pharmaceutical Products: Implications for Patient Safety Enthalten in Drugs - real world outcomes Bd. 7, 22.4.2020, Nr. 2, date:6.2020: 131-139
	97	Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis Enthalten in Arthritis Research & Therapy Bd. 27, 17.7.2025, Nr. 1, date:12.2025: 1-7
	98	Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review Enthalten in Advances in therapy Bd. 36, 5.6.2019, Nr. 8, date:8.2019: 1851-1877
	99	Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study Enthalten in Drug safety Bd. 42, 21.6.2019, Nr. 12, date:12.2019: 1437-1447
	100	Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC) Enthalten in BioDrugs Bd. 35, 15.7.2021, Nr. 4, date:7.2021: 417-428

91 - 100 von 138

Alle Materialarten

Alle Kataloge/Sammlungen

Alle Standorte > Leipzig (138)

Aktionen

Administration